California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...

a device that attaches to its Tempo insulin delivery pen rang, and has said it intends to being it to market in Europe this year. A similar add-on approach is being taken by Sanofi for its ...

The US FDA has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes.

Sanofi India Limited announced the launch of AllStar, its first indigenously manufactured re-usable insulin pen.On 14 February 2013, Sanofi India Limited announced the launch of Combiflam Plus ...

This growth comes on the back of a steady market performance from 2017 to 2022, where the injection pen sector achieved a ...

Novo Nordisk has introduced all-in-one, connected insulin pens that use near-field communication (NFC) to communicate with an app, while Sanofi has taken a similar approach to Lilly, developing an ...

As we enter 2025, our priority is to establish partnerships for M1Pram with Sanofi and for BioChaperone ... of a single-use pen device. BioChaperone® CagriSema is expected to offer significant ...

vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill ...

A SoloStar™ prefilled (disposable) pen containing 3 mL of 100 units/mL insulin glargine and 33 μg/mL lixisenatide ... Disclosure: This research was supported by Sanofi. Multiple study authors declared ...